Intestinal Permeability Defects: Is It Time to Treat?

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 9, 2013, Pages 1075-1083

  Odenwald, Matthew A ^a   Turner, Jerrold R ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Claudin; Graft vs Host Disease; Inflammatory Bowel Disease; Irritable Bowel Syndrome; Leaky Gut Syndrome; Myosin Light Chain Kinase; Tight Junction

Indexed keywords

ACUTE PANCREATITIS; ALCOHOLISM; ARTICLE; ASTHMA; CELIAC DISEASE; CHRONIC FATIGUE SYNDROME; CROHN DISEASE; DEPRESSION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ECZEMA; ENTEROPATHY; FIBROMYALGIA; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINAL PERMEABILITY DEFECT; KWASHIORKOR; LIVER CIRRHOSIS; MULTIPLE ORGAN FAILURE; MULTIPLE SCLEROSIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PSORIASIS; RHEUMATIC DISEASE; ULCERATIVE COLITIS;

CA-MLCK; CD; CLAUDIN; CONSTITUTIVELY ACTIVE-MYOSIN LIGHT CHAIN KINASE; CROHN'S DISEASE; GRAFT VS HOST DISEASE; GRAFT-VERSUS-HOST DISEASE; GVHD; IBD; IBS; IL; INFLAMMATORY BOWEL DISEASE; INTERLEUKIN; IRRITABLE BOWEL SYNDROME; LEAKY GUT SYNDROME; MLCK; MYOSIN LIGHT CHAIN KINASE; TIGHT JUNCTION; TNF; TUMOR NECROSIS FACTOR;

GASTROINTESTINAL DISEASES; HUMANS; INTESTINAL MUCOSA; PERMEABILITY;

EID: 84882797836     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.07.001     Document Type: Article

References (110)

1. Turner J.R. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 2009, 9:799-809.
2. Johansson M.E., Phillipson M., Petersson J., et al. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci U S A 2008, 105:15064-15069.
3. Levitt M.D., Furne J.K., Strocchi A., et al. Physiological measurements of luminal stirring in the dog and human small bowel. J Clin Invest 1990, 86:1540-1547.
4. Van der Sluis M., De Koning B.A., De Bruijn A.C., et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 2006, 131:117-129.
5. Kottra G., Fromter E. Functional properties of the paracellular pathway in some leaky epithelia. J Exp Biol 1983, 106:217-229.
6. Shen L., Weber C.R., Raleigh D.R., et al. Tight junction pore and leak pathways: a dynamic duo. Annu Rev Physiol 2011, 73:283-309.
7. Francis S.A., Kelly J.M., McCormack J., et al. Rapid reduction of MDCK cell cholesterol by methyl-beta-cyclodextrin alters steady state transepithelial electrical resistance. Eur J Cell Biol 1999, 78:473-484.
8. Marchiando A.M., Graham W.V., Turner J.R. Epithelial barriers in homeostasis and disease. Annu Rev Pathol 2010, 5:119-144.
9. Schulzke J.D., Ploeger S., Amasheh M., et al. Epithelial tight junctions in intestinal inflammation. Ann N Y Acad Sci 2009, 1165:294-300.
10. Anderson J.M., Van Itallie C.M. Physiology and function of the tight junction. Cold Spring Harb Perspect Biol 2009, 1:a002584.
11. Van Itallie C.M., Anderson J.M. Claudins and epithelial paracellular transport. Annu Rev Physiol 2006, 68:403-429.
12. Tang V.W., Goodenough D.A. Paracellular ion channel at the tight junction. Biophys J 2003, 84:1660-1673.
13. Madara J.L. Increases in guinea pig small intestinal transepithelial resistance induced by osmotic loads are accompanied by rapid alterations in absorptive-cell tight-junction structure. J Cell Biol 1983, 97:125-136.
14. Madara J.L., Barenberg D., Carlson S. Effects of cytochalasin D on occluding junctions of intestinal absorptive cells: further evidence that the cytoskeleton may influence paracellular permeability and junctional charge selectivity. J Cell Biol 1986, 102:2125-2136.
15. Fihn B.M., Sjoqvist A., Jodal M. Permeability of the rat small intestinal epithelium along the villus-crypt axis: effects of glucose transport. Gastroenterology 2000, 119:1029-1036.
16. Clayburgh D.R., Barrett T.A., Tang Y., et al. Epithelial myosin light chain kinase-dependent barrier dysfunction mediates T cell activation-induced diarrhea in vivo. J Clin Invest 2005, 115:2702-2715.
17. Weber C.R., Raleigh D.R., Su L., et al. Epithelial myosin light chain kinase activation induces mucosal interleukin-13 expression to alter tight junction ion selectivity. J Biol Chem 2010, 285:12037-12046.
18. Jodal M., Fihn B.-M., Sjøqvist A. Effect of glucose on passive transport of extracellular probes across the rat small intestinal epithelium in vivo. Gastroenterology 1994, 107:A241.
19. Watson C.J., Hoare C.J., Garrod D.R., et al. Interferon-gamma selectively increases epithelial permeability to large molecules by activating different populations of paracellular pores. J Cell Sci 2005, 118:5221-5230.
20. Watson C.J., Rowland M., Warhurst G. Functional modeling of tight junctions in intestinal cell monolayers using polyethylene glycol oligomers. Am J Physiol Cell Physiol 2001, 281:C388-C397.
21. Van Itallie C.M., Holmes J., Bridges A., et al. The density of small tight junction pores varies among cell types and is increased by expression of claudin-2. J Cell Sci 2008, 121:298-305.
22. Heller F., Florian P., Bojarski C., et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 2005, 129:550-564.
23. Amasheh S., Meiri N., Gitter A.H., et al. Claudin-2 expression induces cation-selective channels in tight junctions of epithelial cells. J Cell Sci 2002, 115:4969-4976.
24. Rosenthal R., Milatz S., Krug S.M., et al. Claudin-2, a component of the tight junction, forms a paracellular water channel. J Cell Sci 2010, 123:1913-1921.
25. Zolotarevsky Y., Hecht G., Koutsouris A., et al. A membrane-permeant peptide that inhibits MLC kinase restores barrier function in in vitro models of intestinal disease. Gastroenterology 2002, 123:163-172.
26. Blair S.A., Kane S.V., Clayburgh D.R., et al. Epithelial myosin light chain kinase expression and activity are upregulated in inflammatory bowel disease. Lab Invest 2006, 86:191-201.
27. Krug S.M., Fromm M., Gunzel D. Two-path impedance spectroscopy for measuring paracellular and transcellular epithelial resistance. Biophys J 2009, 97:2202-2211.
28. Meddings J.B., Gibbons I. Discrimination of site-specific alterations in gastrointestinal permeability in the rat. Gastroenterology 1998, 114:83-92.
29. Camilleri M., Lasch K., Zhou W. Irritable bowel syndrome: methods, mechanisms, and pathophysiology-the confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2012, 303:G775-G785.
30. Rao A.S., Camilleri M., Eckert D.J., et al. Urine sugars for in vivo gut permeability: validation and comparisons in irritable bowel syndrome-diarrhea and controls. Am J Physiol Gastrointest Liver Physiol 2011, 301:G919-G928.
31. +-glucose cotransport. Dig Dis Sci 2000, 45:2122-2126.
32. Turner J.R., Rill B.K., Carlson S.L., et al. Physiological regulation of epithelial tight junctions is associated with myosin light-chain phosphorylation. Am J Physiol 1997, 273:C1378-C1385.
33. Meddings J.B., Westergaard H. Intestinal glucose transport using perfused rat jejunum in vivo: model analysis and derivation of corrected kinetic constants. Clin Sci (Lond) 1989, 76:403-413.
34. Atisook K., Carlson S., Madara J.L. Effects of phlorizin and sodium on glucose-elicited alterations of cell junctions in intestinal epithelia. Am J Physiol 1990, 258:C77-C85.
35. Ramakrishna B.S., Venkataraman S., Srinivasan P., et al. Amylase-resistant starch plus oral rehydration solution for cholera. N Engl J Med 2000, 342:308-313.
36. Hollander D., Vadheim C.M., Brettholz E., et al. Increased intestinal permeability in patients with Crohn's disease and their relatives: a possible etiologic factor. Ann Intern Med 1986, 105:883-885.
37. May G.R., Sutherland L.M., Meddings J.B. Lactulose/mannitol permeability is increased in relatives of patients with Crohn's disease. Gastroenterology 1992, 102:A934.
38. Buhner S., Buning C., Genschel J., et al. Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD15 3020insC mutation?. Gut 2006, 55:342-347.
39. Wyatt J., Vogelsang H., Hubl W., et al. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 1993, 341:1437-1439.
40. D'Inca R., Di Leo V., Corrao G., et al. Intestinal permeability test as a predictor of clinical course in Crohn's disease. Am J Gastroenterol 1999, 94:2956-2960.
41. Bitton A., Dobkin P., Edwardes M.D., et al. Predicting relapse in Crohn's disease: a biopsychosocial model. Gut 2008, 57:1386-1392.
42. Meddings J.B., Swain M.G. Environmental stress-induced gastrointestinal permeability is mediated by endogenous glucocorticoids in the rat. Gastroenterology 2000, 119:1019-1028.
43. Boirivant M., Amendola A., Butera A., et al. A transient breach in the epithelial barrier leads to regulatory T-cell generation and resistance to experimental colitis. Gastroenterology 2008, 135:1612-1623.
44. Arrieta M.C., Madsen K., Doyle J., et al. Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse. Gut 2009, 58:41-48.
45. Watts T., Berti I., Sapone A., et al. Role of the intestinal tight junction modulator zonulin in the pathogenesis of type I diabetes in BB diabetic-prone rats. Proc Natl Acad Sci U S A 2005, 102:2916-2921.
46. Kelly C.P., Green P.H.R., Murray J.A., et al. Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study. Aliment Pharmacol Ther 2013, 37:252-262.
47. Su L., Shen L., Clayburgh D.R., et al. Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis. Gastroenterology 2009, 136:551-563.
48. May G.R., Sutherland L.R., Meddings J.B. Is small intestinal permeability really increased in relatives of patients with Crohn's disease?. Gastroenterology 1993, 104:1627-1632.
49. Gradel K.O., Nielsen H.L., Schonheyder H.C., et al. Increased short- and long-term risk of inflammatory bowel disease after salmonella or campylobacter gastroenteritis. Gastroenterology 2009, 137:495-501.
50. Villani A.C., Lemire M., Thabane M., et al. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology 2010, 138:1502-1513.
51. Su L., Nalle S.C., Shen L., et al. TNFR2 activates MLCK-dependent tight junction dysregulation to cause apoptosis-mediated barrier loss and experimental colitis. Gastroenterology 2013, 145:407-415.
52. Borody T.J., Warren E.F., Leis S., et al. Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol 2003, 37:42-47.
53. Summers R.W., Elliott D.E., Qadir K., et al. Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease. Am J Gastroenterol 2003, 98:2034-2041.
54. Madsen K.L., Malfair D., Gray D., et al. Interleukin-10 gene-deficient mice develop a primary intestinal permeability defect in response to enteric microflora. Inflamm Bowel Dis 1999, 5:262-270.
55. Suenaert P., Bulteel V., Lemmens L., et al. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol 2002, 97:2000-2004.
56. Scheinin T., Butler D.M., Salway F., et al. Validation of the interleukin-10 knockout mouse model of colitis: antitumour necrosis factor-antibodies suppress the progression of colitis. Clin Exp Immunol 2003, 133:38-43.
57. Johansson J.E., Ekman T. Gut toxicity during hemopoietic stem cell transplantation may predict acute graft-versus-host disease severity in patients. Dig Dis Sci 2007, 52:2340-2345.
58. Brown G.R., Lindberg G., Meddings J., et al. Tumor necrosis factor inhibitor ameliorates murine intestinal graft-versus-host disease. Gastroenterology 1999, 116:593-601.
59. Heidt P.J., Vossen J.M. Experimental and clinical gnotobiotics: influence of the microflora on graft-versus-host disease after allogeneic bone marrow transplantation. J Med 1992, 23:161-173.
60. Beelen D.W., Elmaagacli A., Muller K.D., et al. Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospective randomized trial. Blood 1999, 93:3267-3275.
61. Bosi E., Molteni L., Radaelli M.G., et al. Increased intestinal permeability precedes clinical onset of type 1 diabetes. Diabetologia 2006, 49:2824-2827.
62. Meddings J.B., Jarand J., Urbanski S.J., et al. Increased gastrointestinal permeability is an early lesion in the spontaneously diabetic BB rat. Am J Physiol 1999, 276:G951-G957.
63. Wen L., Ley R.E., Volchkov P.Y., et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 2008, 455:1109-1113.
64. Pozzilli P., Signore A., Williams A.J., et al. NOD mouse colonies around the world: recent facts and figures. Immunol Today 1993, 14:193-196.
65. Sharpstone D., Neild P., Crane R., et al. Small intestinal transit, absorption, and permeability in patients with AIDS with and without diarrhoea. Gut 1999, 45:70-76.
66. Keating J., Bjarnason I., Somasundaram S., et al. Intestinal absorptive capacity, intestinal permeability and jejunal histology in HIV and their relation to diarrhoea. Gut 1995, 37:623-629.
67. Brenchley J.M., Price D.A., Schacker T.W., et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006, 12:1365-1371.
68. Epple H.J., Schneider T., Troeger H., et al. Impairment of the intestinal barrier is evident in untreated but absent in suppressively treated HIV-infected patients. Gut 2009, 58:220-227.
69. Doig C.J., Sutherland L.R., Sandham J.D., et al. Increased intestinal permeability is associated with the development of multiple organ dysfunction syndrome in critically ill ICU patients. Am J Respir Crit Care Med 1998, 158:444-451.
70. Fink M.P., Antonsson J.B., Wang H.L., et al. Increased intestinal permeability in endotoxic pigs: mesenteric hypoperfusion as an etiologic factor. Arch Surg 1991, 126:211-218.
71. Deitch E.A., Morrison J., Berg R., et al. Effect of hemorrhagic shock on bacterial translocation, intestinal morphology, and intestinal permeability in conventional and antibiotic-decontaminated rats. Crit Care Med 1990, 18:529-536.
72. Dunlop S.P., Hebden J., Campbell E., et al. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 2006, 101:1288-1294.
73. Marshall J.K., Thabane M., Garg A.X., et al. Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment Pharmacol Ther 2004, 20:1317-1322.
74. Smecuol E., Bai J.C., Vazquez H., et al. Gastrointestinal permeability in celiac disease. Gastroenterology 1997, 112:1129-1136.
75. van Elburg R.M., Uil J.J., Mulder C.J., et al. Intestinal permeability in patients with coeliac disease and relatives of patients with coeliac disease. Gut 1993, 34:354-357.
76. Natividad J.M., Huang X., Slack E., et al. Host responses to intestinal microbial antigens in gluten-sensitive mice. PLoS One 2009, 4:e6472.
77. Verdu E.F., Huang X., Natividad J., et al. Gliadin-dependent neuromuscular and epithelial secretory responses in gluten-sensitive HLA-DQ8 transgenic mice. Am J Physiol Gastrointest Liver Physiol 2008, 294:G217-G225.
78. de Magistris L., Familiari V., Pascotto A., et al. Alterations of the intestinal barrier in patients with autism spectrum disorders and in their first-degree relatives. J Pediatr Gastroenterol Nutr 2010, 51:418-424.
79. Pike M.G., Heddle R.J., Boulton P., et al. Increased intestinal permeability in atopic eczema. J Invest Dermatol 1986, 86:101-104.
80. Jackson P.G., Lessof M.H., Baker R.W., et al. Intestinal permeability in patients with eczema and food allergy. Lancet 1981, 1:1285-1286.
81. Ammori B.J., Leeder P.C., King R.F., et al. Early increase in intestinal permeability in patients with severe acute pancreatitis: correlation with endotoxemia, organ failure, and mortality. J Gastrointest Surg 1999, 3:252-262.
82. Foitzik T., Fernandez-del Castillo C., Ferraro M.J., et al. Pathogenesis and prevention of early pancreatic infection in experimental acute necrotizing pancreatitis. Ann Surg 1995, 222:179-185.
83. Ryan C.M., Schmidt J., Lewandrowski K., et al. Gut macromolecular permeability in pancreatitis correlates with severity of disease in rats. Gastroenterology 1993, 104:890-895.
84. Foitzik T., Stufler M., Hotz H.G., et al. Glutamine stabilizes intestinal permeability and reduces pancreatic infection in acute experimental pancreatitis. J Gastrointest Surg 1997, 1:40-47.
85. Salat-Foix D., Tran K., Ranawaya R., et al. Increased intestinal permeability and Parkinson disease patients: chicken or egg?. Can J Neurol Sci 2012, 39:185-188.
86. Davies K.N., King D., Billington D., et al. Intestinal permeability and orocaecal transit time in elderly patients with Parkinson's disease. Postgrad Med J 1996, 72:164-167.
87. Goebel A., Buhner S., Schedel R., et al. Altered intestinal permeability in patients with primary fibromyalgia and in patients with complex regional pain syndrome. Rheumatology (Oxford) 2008, 47:1223-1227.
88. Pimentel M., Wallace D., Hallegua D., et al. A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing. Ann Rheum Dis 2004, 63:450-452.
89. Hijazi Z., Molla A.M., Al-Habashi H., et al. Intestinal permeability is increased in bronchial asthma. Arch Dis Child 2004, 89:227-229.
90. Umetsu D.T., McIntire J.J., Akbari O., et al. Asthma: an epidemic of dysregulated immunity. Nat Immunol 2002, 3:715-720.
91. Yacyshyn B., Meddings J., Sadowski D., et al. Multiple sclerosis patients have peripheral blood CD45RO+ B cells and increased intestinal permeability. Dig Dis Sci 1996, 41:2493-2498.
92. Lee Y.K., Menezes J.S., Umesaki Y., et al. Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 2011, 108(Suppl 1):4615-4622.
93. Martinez-Gonzalez O., Cantero-Hinojosa J., Paule-Sastre P., et al. Intestinal permeability in patients with ankylosing spondylitis and their healthy relatives. Br J Rheumatol 1994, 33:644-647.
94. Morris A.J., Howden C.W., Robertson C., et al. Increased intestinal permeability in ankylosing spondylitis: primary lesion or drug effect?. Gut 1991, 32:1470-1472.
95. Taurog J.D., Richardson J.A., Croft J.T., et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994, 180:2359-2364.
96. Wu H.J., Ivanov I.I., Darce J., et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 2010, 32:815-827.
97. Wigg A.J., Roberts-Thomson I.C., Dymock R.B., et al. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001, 48:206-211.
98. Farhadi A., Gundlapalli S., Shaikh M., et al. Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. Liver Int 2008, 28:1026-1033.
99. Cope K., Risby T., Diehl A.M. Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis. Gastroenterology 2000, 119:1340-1347.
100. Bergheim I., Weber S., Vos M., et al. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J Hepatol 2008, 48:983-992.
101. Keshavarzian A., Holmes E.W., Patel M., et al. Leaky gut in alcoholic cirrhosis: a possible mechanism for alcohol-induced liver damage. Am J Gastroenterol 1999, 94:200-207.
102. Cesaro C., Tiso A., Del Prete A., et al. Gut microbiota and probiotics in chronic liver diseases. Dig Liver Dis 2011, 43:431-438.
103. Kukuruzovic R.H., Brewster D.R. Small bowel intestinal permeability in Australian aboriginal children. J Pediatr Gastroenterol Nutr 2002, 35:206-212.
104. Kukuruzovic R., Robins-Browne R.M., Anstey N.M., et al. Enteric pathogens, intestinal permeability and nitric oxide production in acute gastroenteritis. Pediatr Infect Dis J 2002, 21:730-739.
105. Ritchie B.K., Brewster D.R., Davidson G.P., et al. 13C-sucrose breath test: novel use of a noninvasive biomarker of environmental gut health. Pediatrics 2009, 124:620-626.
106. Korpe P.S., Petri W.A. Environmental enteropathy: critical implications of a poorly understood condition. Trends Mol Med 2012, 18:328-336.
107. Kelly P., Menzies I., Crane R., et al. Responses of small intestinal architecture and function over time to environmental factors in a tropical population. Am J Trop Med Hyg 2004, 70:412-419.
108. Brewster D.R., Manary M.J., Menzies I.S., et al. Intestinal permeability in kwashiorkor. Arch Dis Child 1997, 76:236-241.
109. Lunn P.G., Northrop C.A., Wainwright M. Hypoalbuminemia in energy-malnourished rats infected with Nippostrongylus brasiliensis (Nematoda). J Nutr 1988, 118:121-127.
110. Smith M.I., Yatsunenko T., Manary M.J., et al. Gut microbiomes of Malawian twin pairs discordant for Kwashiorkor. Science 2013, 339:548-554.